Evidence supports considering clozapine earlier in the treatment sequence for early-stage schizophrenia, particularly after initial nonresponse or relapse. System-level interventions and emerging biomarker-guided strategies may reduce delays and improve long-term outcomes.
Davani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: